• bioAffinity Technologies entered a distribution agreement with AvMEDICAL to sell CyPath Lung across the US federal healthcare market.
• Deal targets government procurement channels, including the Department of Veterans Affairs, to expand access to the lung-cancer risk test.
• AvMEDICAL will market CyPath Lung to federal customers using its contracting vehicles, aiming to simplify purchasing and speed adoption.
• CyPath Lung is a noninvasive test for assessing indeterminate pulmonary nodules; it is run by bioAffinity’s Precision Pathology Laboratory Services.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260818742902) on August 18, 2026, and is solely responsible for the information contained therein.